Changes Between Lenticule Extraction and Femtosecond Laser-assisted Laser in Situ Keratomileusis

June 13, 2016 updated by: Xingwu Zhong, MD PhD, Sun Yat-sen University

Comparison of Early Changes in Ocular Surface and Inflammatory Mediators Between Lenticule Extraction and Femtosecond Laser-assisted Laser in Situ Keratomileusis

The aim is to evaluate the short-term changes in ocular surface measures and tear inflammatory mediators after lenticule extraction (FLEx) and femtosecond laser-assisted laser in situ keratomileusis (FS-LASIK) procedures.

Study Overview

Detailed Description

Over the past few years, laser in situ keratomileusis with a femtosecond laser-created flap (FS-LASIK)has been a popular ophthalmic procedure for the correction of refractive error. This first all-in-one FS-laser system was designed to perform the refractive lenticule extraction (ReLEx) procedures, femtosecond lenticule extraction (FLEx).They have the same feature: corneal flap.

Ocular surface disruption during corneal refractive surgery is commonly considered to be closely related to the development of dry eye. Multiple etiologies contribute to this ocular surface disruption, including the flap creation and stromal ablation involved in previous refractive surgery techniques. Corneal nerve damage has been considered the main cause of dry eye, due to disrupted afferent sensory nerves, reduced blink reflex, and increased tear evaporation leading to tear film instability. In addition, postoperative inflammatory mediator fluctuations are also a key factor related to ocular surface damage. Extensive research has described the effects of cytokines, chemokines and growth factors in modulating corneal wound healing, cell migration, and apoptosis on the ocular surface after refractive surgery.

This prospective clinical study is going to assess the short-term changes in ocular surface measures and tear inflammatory mediators after lenticule extraction (FLEx) and femtosecond laser-assisted laser in situ keratomileusis (FS-LASIK) procedures.

Study Type

Interventional

Enrollment (Actual)

75

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Hainan
      • Haikou, Hainan, China, 570311
        • Hainan Eye Hospital, Zhongshan Ophthalmic Center of Sun Yat-sen University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 30 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • minimum age of 18 years(range from 18 year to 25 years)
  • corneal thickness 500 μm with calculated residual stromal bed after treatment greater than 300 μm
  • preoperative spherical equivalent refraction between- 2.00 diopter (D) and -6.50 D.preoperative cylindrical equivalent refraction between -0.25 D and -1.50 D.
  • preoperative corneal curvature from 41.0 D to 46.0 D with a regular topographic pattern monocular best corrected visual acuity of 20/20 or better and stable refractive error (less than 0.5 D change) for 24 months before surgery。

Exclusion Criteria:

  • systemic disease that contraindicated the surgery (such as diabetes, glaucoma and systemic collagen vascular disease)
  • corneal abnormality or disease.
  • a history of tear supplement usage or contact lens wear during the past year.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: lenticule extraction
The patients in this group chose to receive the lenticule extraction surgery
Four femtosecond incisions were created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), and the corneal flap in the superior region. After the suction was released, the flap was opened using a thin, blunt spatula and the free refractive lenticule was subsequently grasped with a forceps and extracted, after which the flap was repositioned carefully.
Experimental: FS assisted laser in situ keratomileusis
The patients in this group chose to receive the femtosecond laser-assisted laser in situ keratomileusis surgery.
track distance and spot distance were 3.0 μm during flap creation and 1.5 μm during flap side-cutting. The flap diameter was 8.0 mm, and flap thickness was set to 105 μm. Side-cut angle and hinge angle were 90°and 50° respectively. The flaps were created by laser scanning in spirals from the periphery to the center of the pupil. An excimer laser system was used in the subsequent ablation of the stromal bed with a 6.0 mm optical zone. Once the excimer ablation was completed, the flap was repositioned in a similar fashion as in routine LASIK.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Schirmer I test
Time Frame: up to 1month after surgery
up to 1month after surgery
corneal fluorescein staining
Time Frame: up to 1month after surgery
up to 1month after surgery
noninvasive tear breakup time
Time Frame: up to 1month after surgery
up to 1month after surgery
ocular surface disease index
Time Frame: up to 1month after surgery
up to 1month after surgery
central corneal sensitivity
Time Frame: up to 1month after surgery
up to 1month after surgery
tear meniscus height
Time Frame: up to 1month after surgery
up to 1month after surgery
Interleukin-1α
Time Frame: up to 1month after surgery
up to 1month after surgery
tumor necrosis factor-α
Time Frame: up to 1month after surgery
up to 1month after surgery
nerve growth factor
Time Frame: up to 1month after surgery
up to 1month after surgery
interferon-γ
Time Frame: up to 1month after surgery
up to 1month after surgery
transforming growth factor-β1
Time Frame: up to 1month after surgery
up to 1month after surgery
matrix metalloproteinase-9
Time Frame: up to 1month after surgery
up to 1month after surgery

Secondary Outcome Measures

Outcome Measure
Time Frame
Correlation Between Inflammatory Mediators and Ocular Surface Changes
Time Frame: up to 1month after surgery
up to 1month after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Xingwu Zhong, MD,PhD, Hainan Eye Hospital, Zhongshan Ophthalmic Center of Sun Yat-sen University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2015

Primary Completion (Actual)

March 1, 2016

Study Completion (Actual)

May 1, 2016

Study Registration Dates

First Submitted

September 13, 2015

First Submitted That Met QC Criteria

September 14, 2015

First Posted (Estimate)

September 15, 2015

Study Record Updates

Last Update Posted (Estimate)

June 14, 2016

Last Update Submitted That Met QC Criteria

June 13, 2016

Last Verified

June 1, 2016

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Astigmatism

Clinical Trials on lenticule extraction

Subscribe